All In Biotech

Drug Trial Radar · NCT05245604

Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients

A Phase Ⅲ, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Study of TJO-087 for Evaluating 32 Weeks Safety and Efficacy in Moderate to Severe Dry Eye Disease Patients

Last checked: Nov 19, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

182

Planned (sponsor's estimate)

Start

Jun 19, 2020

Primary completion

Aug 2022

Study completion Apr 2023

Sponsor

Sponsor type
Industry
First posted
Feb 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to prove that the test drug (TJO-087) is not clinically inferior to the control drug after 32 weeks of administration to patients with suppressed tear production due to moderate or severe dry eye syndrome.

Conditions

  • Dry Eye Syndrome

Interventions

  • TJO-087Drug

    Cyclosporine ophthalmic nano-emulsion 0.08%, 1 drop once daily

  • Cyclosporine ophthalmic solution 0.05%Drug

    Cyclosporine ophthalmic solution 0.05%, 1 drop twice/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Non-anesthetic Schirmer Test at Week 32Time frame: Baseline and Week 32

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hyo Myung, Kim

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.